Australia's Noxopharm surges on drug passing safety tests

Noxopharm

04/02/2025 03:46

** Noxopharm  NOX.AX  soars 12.9% to A$0.096, snapping three
sessions of declines
    ** Stock set for biggest intraday pct gain since Nov. 15,
2024
    ** Biotech co says its lupus medication has passed a set of
pre-clinical safety tests, a requisite for drug development
prior to Phase 1 clinical trial
    ** Around 326,347 shares traded, 2.3x the 30-day avg
    ** NOX gains 3.2% YTD

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)
 ((Jasmeenaraislam.shaikh@thomsonreuters.com))